Although many patients with aggressive lymphoma can be cured with standard frontline immunochemotherapies, the rate of relapse and death remains high, particularly in high-risk disease. In recent years, the emergence of new immunotherapies and targeted therapies has improved the prognosis of these patients, but many challenges persist to enhance the management of aggressive lymphomas. This report provides a summary of the most interesting presentations in the field of aggressive lymphoma at ASH 2023.

(BELG J HEMATOL 2024;15(1):13–17)